| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ahmed A Moustafa, Mohamed Salama, Roseanne Peak, Richard Tindle, Amir Salem, Szabolcs Keri, Błażej Misiak, Dorota Frydecka, Wael Mohame. Interactions between cannabis and schizophrenia in humans and rodents. Reviews in the neurosciences. vol 28. issue 7. 2018-03-05. PMID:28498796. |
we finally provide clinical implications and future studies that can further elucidate the relationship between cannabis and schizophrenia. |
2018-03-05 |
2023-08-13 |
human |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
the effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fmri study. |
2018-01-16 |
2023-08-12 |
Not clear |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
cannabis use disorders (cuds) are highly comorbid in patients with schizophrenia and are associated with poor outcome. |
2018-01-16 |
2023-08-12 |
Not clear |
| Ashleigh L Osborne, Nadia Solowij, Ilijana Babic, Xu-Feng Huang, Katrina Weston-Gree. Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 7. 2018-01-12. PMID:28230072. |
cannabidiol (cbd), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. |
2018-01-12 |
2023-08-13 |
rat |
| G Baudin, O Godin, M Lajnef, B Aouizerate, F Berna, L Brunel, D Capdevielle, I Chereau, J M Dorey, C Dubertret, J Dubreucq, C Faget, G Fond, F Gabayet, H Laouamri, C Lancon, Y Le Strat, A M Tronche, D Misdrahi, R Rey, C Passerieux, A Schandrin, M Urbach, P Vidalhet, P M Llorca, F Schürhof. Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophrenia research. vol 175. issue 1-3. 2018-01-02. PMID:27209524. |
differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. |
2018-01-02 |
2023-08-13 |
Not clear |
| G Baudin, O Godin, M Lajnef, B Aouizerate, F Berna, L Brunel, D Capdevielle, I Chereau, J M Dorey, C Dubertret, J Dubreucq, C Faget, G Fond, F Gabayet, H Laouamri, C Lancon, Y Le Strat, A M Tronche, D Misdrahi, R Rey, C Passerieux, A Schandrin, M Urbach, P Vidalhet, P M Llorca, F Schürhof. Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophrenia research. vol 175. issue 1-3. 2018-01-02. PMID:27209524. |
childhood trauma (ct) and cannabis use are both environmental and modifier risk factors for schizophrenia. |
2018-01-02 |
2023-08-13 |
Not clear |
| Anand Gururajan, Daniel Thomas Malon. Does cannabidiol have a role in the treatment of schizophrenia? Schizophrenia research. vol 176. issue 2-3. 2018-01-02. PMID:27374322. |
does cannabidiol have a role in the treatment of schizophrenia? |
2018-01-02 |
2023-08-13 |
Not clear |
| Anand Gururajan, Daniel Thomas Malon. Does cannabidiol have a role in the treatment of schizophrenia? Schizophrenia research. vol 176. issue 2-3. 2018-01-02. PMID:27374322. |
in this regard, cannabidiol (cbd), a non-psychoactive constituent of cannabis sativa, has shown significant promise as a potential antipsychotic for the treatment of schizophrenia. |
2018-01-02 |
2023-08-13 |
Not clear |
| David E Mandelbaum, Suzanne M de la Mont. Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence Reviewed. Pediatric neurology. vol 66. 2017-12-18. PMID:27789118. |
contrary to popular perception, there are few objective data supporting preferential use of cannabis over conventional therapy for restoration of central nervous system structure and function in disease states such as multiple sclerosis, epilepsy, or schizophrenia. |
2017-12-18 |
2023-08-13 |
Not clear |
| Justine Renard, Walter J Rushlow, Steven R Laviolett. What Can Rats Tell Us about Adolescent Cannabis Exposure? Insights from Preclinical Research. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 61. issue 6. 2017-12-08. PMID:27254841. |
increasing preclinical evidence lends support to clinical evidence suggesting that chronic adolescent marijuana exposure may be associated with a higher risk for neuropsychiatric diseases, including schizophrenia. |
2017-12-08 |
2023-08-13 |
rat |
| Thomas Schnell, Rajac Gliese, Romy Schröter, Erich Kasten, Euphrosyne Gouzoulis-Mayfran. Motivational changes of cannabis use prior to and during the course of schizophrenia. The American journal on addictions. vol 26. issue 2. 2017-12-04. PMID:28004866. |
motivational changes of cannabis use prior to and during the course of schizophrenia. |
2017-12-04 |
2023-08-13 |
Not clear |
| Thomas Schnell, Rajac Gliese, Romy Schröter, Erich Kasten, Euphrosyne Gouzoulis-Mayfran. Motivational changes of cannabis use prior to and during the course of schizophrenia. The American journal on addictions. vol 26. issue 2. 2017-12-04. PMID:28004866. |
we investigated subjective reasons/motivation for cannabis use in patients with schizophrenia (n = 51) compared to otherwise healthy cannabis users (n = 109). |
2017-12-04 |
2023-08-13 |
Not clear |
| Kayla A Chase, Benjamin Feiner, Cherise Rosen, David P Gavin, Rajiv P Sharm. Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia. Psychiatry research. vol 245. 2017-11-28. PMID:27591408. |
mrna levels of cbrs were measured in human peripheral blood mononuclear cells (pbmcs) obtained from 70 participants (35 non-clinical controls, 35 participants with schizophrenia), who were recruited for the absence of marijuana use/abuse by self-report. |
2017-11-28 |
2023-08-13 |
human |
| Kayla A Chase, Benjamin Feiner, Cherise Rosen, David P Gavin, Rajiv P Sharm. Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia. Psychiatry research. vol 245. 2017-11-28. PMID:27591408. |
these results continue to support dysregulation of particular aspects of the endocannabinoid signaling system in participants with schizophrenia selected for the self-reported absence of marijuana abuse/dependence. |
2017-11-28 |
2023-08-13 |
human |
| b' S H Gage, H J Jones, S Burgess, J Bowden, G Davey Smith, S Zammit, M R Munaf\\xc3\\xb. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychological medicine. vol 47. issue 5. 2017-11-28. PMID:27928975.' |
assessing causality in associations between cannabis use and schizophrenia risk: a two-sample mendelian randomization study. |
2017-11-28 |
2023-08-13 |
Not clear |
| b' S H Gage, H J Jones, S Burgess, J Bowden, G Davey Smith, S Zammit, M R Munaf\\xc3\\xb. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychological medicine. vol 47. issue 5. 2017-11-28. PMID:27928975.' |
observational associations between cannabis and schizophrenia are well documented, but ascertaining causation is more challenging. |
2017-11-28 |
2023-08-13 |
Not clear |
| Siri Helle, Else-Marie Løberg, Rolf Gjestad, Ashley M Schnakenberg Martin, Paul H Lysake. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry research. vol 250. 2017-11-16. PMID:28152399. |
the positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. |
2017-11-16 |
2023-08-13 |
Not clear |
| Siri Helle, Else-Marie Løberg, Rolf Gjestad, Ashley M Schnakenberg Martin, Paul H Lysake. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry research. vol 250. 2017-11-16. PMID:28152399. |
there has been a growing link between a history of cannabis use and neurocognitive performance in patients with schizophrenia. |
2017-11-16 |
2023-08-13 |
Not clear |
| Siri Helle, Else-Marie Løberg, Rolf Gjestad, Ashley M Schnakenberg Martin, Paul H Lysake. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry research. vol 250. 2017-11-16. PMID:28152399. |
fewer neurocognitive deficits may be a marker of the superior social cognition needed to obtain illicit substances, or cannabis use may indicate a distinct path to schizophrenia with less neurocognitive vulnerability. |
2017-11-16 |
2023-08-13 |
Not clear |
| Ashleigh L Osborne, Nadia Solowij, Katrina Weston-Gree. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neuroscience and biobehavioral reviews. vol 72. 2017-10-25. PMID:27884751. |
a systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. |
2017-10-25 |
2023-08-13 |
Not clear |